Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity.
Katja BenderJohannes KahnEilís PerezFelix EhretSiyer RoohaniDavid CapperSimone SchmidDavid KaulPublished in: Brain tumor pathology (2023)
Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype (pHGG) is a rare and aggressive brain tumor characterized by a specific DNA methylation profile. It was recently introduced in the 5th World Health Organization classification of central nervous system tumors of 2021. Clinical data on this tumor is scarce. This is a case series, which presents the first clinical experience with this entity. We compiled a retrospective case series on pHGG patients treated between 2015 and 2022 at our institution. Data collected include patients' clinical course, surgical procedure, histopathology, genome-wide DNA methylation analysis, imaging and adjuvant therapy. Eight pHGG were identified, ranging in age from 8 to 71 years. On MRI tumors presented with an unspecific intensity profile, T1w hypo- to isointense and T2w hyperintense, with inhomogeneous contrast enhancement, often with rim enhancement. Three patients died of the disease, with overall survival of 19, 28 and 30 months. Four patients were alive at the time of the last follow-up, 4, 5, 6 and 79 months after the initial surgery. One patient was lost to follow-up. Findings indicate that pHGG prevalence might be underestimated in the elderly population.
Keyphrases
- dna methylation
- high grade
- end stage renal disease
- genome wide
- low grade
- ejection fraction
- newly diagnosed
- chronic kidney disease
- magnetic resonance imaging
- prognostic factors
- peritoneal dialysis
- minimally invasive
- high resolution
- magnetic resonance
- coronary artery disease
- deep learning
- big data
- photodynamic therapy
- mass spectrometry
- percutaneous coronary intervention
- acute coronary syndrome
- copy number